ArticleClinical rheumatology2026
Associations between SARC-F score and FRAX score in patients with rheumatoid arthritis: A cross-sectional study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRheumatoid arthritis (RA) increases the risk of osteoporotic fractures due to chronic inflammation, glucocorticoid use, and reduced muscle mass. Sarcopenia, frequently underdiagnosed in RA, may contribute independently to skeletal fragility. This study aimed to determine the associations between sarcopenia risk, by the SARC-F screening tool, and 10-year fracture probability, calculated via FRAX, in patients with RA. MATERIALS AND
methodsA cross-sectional, retrospective study was conducted among 66 patients with RA aged ≥ 40 years in Mexico. Sarcopenia risk was assessed using the SARC-F questionnaire. Muscle mass was measured via dual-energy X-ray absorptiometry (DXA), and sarcopenia was defined according to EWGSOP2 criteria. Fracture risk was calculated using the Mexican FRAX tool. Four fracture risk scores were calculated: major osteoporotic and hip fracture risk, each assessed with and without bone mineral density (BMD).
resultsSixty percent of participants were at high risk of sarcopenia (SARC-F ≥ 4), and 33.3% met EWGSOP2 sarcopenia criteria. SARC-F scores correlated negatively with femoral neck T-scores (r = -0.306, p = 0.013) and muscle mass (r = -0.390, p = 0.001). Significant weak-to-moderate positive correlations were observed between SARC-F and FRAX-predicted fracture risk (MOF-FRAX: r = 0.354 and 0.310; HF-FRAX: r = 0.294 and 0.267; all p < 0.05). SARC-F scores were significantly higher in patients classified as high fracture risk (p = 0.035).
conclusionSarcopenia risk, as measured by SARC-F, is significantly associated with increased FRAX-estimated fracture risk in RA patients. Incorporating SARC-F into routine assessments may improve early identification of patients at high fracture risk. Key Points • Sarcopenia is common in rheumatoid arthritis and is frequently under-detected. • Higher sarcopenia risk is associated with poorer bone health and increased fracture probability. • Simple screening tools, such as SARC-F, may help identify RA patients at elevated fracture risk earlier in clinical practice.
Indexed as
Identifiers
42414820What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.